PharmaTimes reports that Johnson & Johnson has withdrawn a European filing for its investigational epilepsy drug carbisamate (Comfyde®). The filing was for the adjunctive treatment of partial onset seizures with or without secondary generalisation in patients aged 16 or older. According to PharmaTimes, the company has said that the decision to withdraw the application was based on the feedback from the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP). The CHMP advised that it was unlikely to reach a favourable opinion “without additional efficacy data, which at this time cannot be provided”.